Aspargo Labs Inc.
Sildenafil Oral Spray
Press Release
January 24, 2023
Aspargo Receives Regulatory Approval to Market Sildenafil Spray in Germany, Ireland, and The Netherlands
Read More
November 29, 2022
Aspargo Extends Latin America Reach From Mexico To Argentina
Read More
October 4, 2022
Aspargo’s Footprint Grows With Middle East Expansion
Read More
June 21, 2022
Aspargo Expands Beyond Spain Into Latin America
Read More
May 20, 2022
Aspargo Acquires Bandol® Sildenafil Spray
Read More
September 29, 2020
Aspargo Acquires International Rights to Sildenafil Oral Spray
Read More
May 4, 2020
Aspargo Announces Successful Completion of Pre-IND Meeting w/ FDA
Read More
Corporate Presentation
Footer
Aspargo Laboratories, Inc. is a clinical-stage biopharmaceutical company developing patient-focused solutions and must-have medicines by combining our innovative science and technologies with FDA’s 505(b)(2) approval pathway and corresponding regulations in international jurisdictions to enhance currently marketed drugs with well-known pharmacology profiles.